Genprex, Inc., based in Austin, TX, has announced the initiation of a Phase 1/2 clinical trial for Quaratusugene Ozeplasmid gene therapy combined with Atezolizumab maintenance therapy in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). This study aims to evaluate the efficacy and safety of the TUSC2 gene encapsulated in lipid-based nanoparticles. The trial will include patients who have shown a complete response, partial response, or stable disease after receiving three to four cycles of standard treatment, which includes atezolizumab, carboplatin, and etoposide. The study's design and methodology include a futility analysis after the 25th patient reaches 18 weeks of follow-up, with patient eligibility criteria focusing on those with an ECOG Performance Status of 0 to 1. Further details are available on Genprex's official website.